MONCTON, N.B. – The Atlantic Cancer Research Institute has partnered with Boston-based biotech company New England Peptide to create up to 15 highly skilled jobs in Moncton over the next three years.
The two organizations have founded a company, Excipio Technologies, that will bring new research to market that will allow easier detection of diseases including Alzheimer’s and cancer.
And NEP president Sam Massoni says detection could just be the beginning.
“The technology is simple. It works really well. We’ve proved it works in a variety of different ways and, obviously, it’s applicable to all disease.”
Massoni says patients will benefit the most from the new technology because it allows doctors to diagnose diseases more quickly and in a less invasive way than current methods.